KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Research & Development (2016 - 2025)

Biogen (BIIB) has 17 years of Research & Development data on record, last reported at $509.4 million in Q4 2025.

  • For Q4 2025, Research & Development rose 0.91% year-over-year to $509.4 million; the TTM value through Dec 2025 reached $1.8 billion, down 10.19%, while the annual FY2025 figure was $1.8 billion, 10.19% down from the prior year.
  • Research & Development reached $509.4 million in Q4 2025 per BIIB's latest filing, up from $436.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $1.6 billion in Q3 2023 and bottomed at $399.0 million in Q2 2025.
  • Average Research & Development over 5 years is $587.8 million, with a median of $538.9 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 1600.73% in 2021, then plummeted 66.83% in 2024.
  • A 5-year view of Research & Development shows it stood at $699.5 million in 2021, then dropped by 14.0% to $601.6 million in 2022, then decreased by 7.86% to $554.3 million in 2023, then decreased by 8.93% to $504.8 million in 2024, then grew by 0.91% to $509.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $509.4 million in Q4 2025, $436.1 million in Q3 2025, and $399.0 million in Q2 2025.